{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:06Z","timestamp":1740144126131,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40266-020-00781-y","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T07:03:32Z","timestamp":1595315012000},"page":"657-663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7315-9600","authenticated-orcid":false,"given":"C\u00e9line","family":"Phan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Beneton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Delaunay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad","family":"Reguiai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Boulard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Claire","family":"Fougerousse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Cinotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Mery-Bossard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domitille","family":"Thomas-Beaulieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josiane","family":"Parier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Maccari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Chaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Bastien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Begon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahtab","family":"Samimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Prignano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Beauchet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the GEM Resopso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireille","family":"Ruer-Mulard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Jacobzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Quiles-Tsimaratos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maud","family":"Steff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Bilan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Vermersch-Langlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Kemula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Amazan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Kupfer-Bessaguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Caroline","family":"Cottencin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulai","family":"Livideanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"781_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/jdv.12850","volume":"30","author":"C Phan","year":"2016","unstructured":"Phan C, Sigal ML, Est\u00e8ve E, et al. Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. J Eur Acad Dermatol Venereol. 2016;30:78\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"781_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00403-002-0321-3","volume":"294","author":"P Stuart","year":"2002","unstructured":"Stuart P, Malick F, Nair RP. Analysis of phenotypic variation in psoriasis as a function of age at onset and family history. Arch Dermatol Res. 2002;294:207\u201313.","journal-title":"Arch Dermatol Res"},{"key":"781_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0190-9622(85)70188-0","volume":"13","author":"T Henseler","year":"1985","unstructured":"Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13:450\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"781_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-4632.2011.04979.x","volume":"51","author":"HH Kwon","year":"2012","unstructured":"Kwon HH, Kwon IH, Youn JI. Clinical study of psoriasis occurring over the age of 60\u00a0years: is elderly-onset psoriasis a distinct subtype? Int J Dermatol. 2012;51:53\u20138.","journal-title":"Int J Dermatol"},{"key":"781_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40266-014-0156-6","volume":"31","author":"N Balato","year":"2014","unstructured":"Balato N, Patruno C, Napolitano M, et al. Managing moderate-to-severe psoriasis in the elderly. Drugs Aging. 2014;31:233\u20138.","journal-title":"Drugs Aging"},{"key":"781_CR6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/14712598.2018.1504016","volume":"18","author":"V Di Lernia","year":"2018","unstructured":"Di Lernia V, Goldust M. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. Expert Opin Biol Ther. 2018;18:897\u2013903.","journal-title":"Expert Opin Biol Ther."},{"key":"781_CR7","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40266-017-0480-8","volume":"34","author":"JG Kamel","year":"2017","unstructured":"Kamel JG, Yamauchi PS. Managing\u00a0mild-to moderate psoriasis in elderly patients: role of topical\u00a0treatments. Drugs Aging. 2017;34:583\u20138.","journal-title":"Drugs Aging"},{"key":"781_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2340\/00015555-1719","volume":"94","author":"S Piaserico","year":"2014","unstructured":"Piaserico S, Conti A, Lo Console F, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94:293\u20137.","journal-title":"Acta Derm Venereol"},{"key":"781_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40266-018-0520-z","volume":"35","author":"A K\u00f6rber","year":"2018","unstructured":"K\u00f6rber A, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. Drugs Aging. 2018;35:135\u201344.","journal-title":"Drugs Aging"},{"key":"781_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jaad.2019.08.019","volume":"82","author":"AS Paller","year":"2020","unstructured":"Paller AS, Hong Y, Becker EM, et al. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study. J Am Acad Dermatol. 2020;82:389\u201397.","journal-title":"J Am Acad Dermatol"},{"key":"781_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16443","author":"M Megna","year":"2020","unstructured":"Megna M, Fabbrocini G, Camela E, et al. Apremilast efficacy and safety in elderly psoriasis patients over a 48-weeks period. J Eur Acad Dermatol Venereol. 2020;. https:\/\/doi.org\/10.1111\/jdv.16443.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"781_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jaad.2017.01.052","volume":"77","author":"J Crowley","year":"2017","unstructured":"Crowley J, Thaci D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for\u2009\u2265\u2009156\u00a0weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77:310\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"781_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37\u201349.","journal-title":"J Am Acad Dermatol"},{"key":"781_CR14","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52\u00a0weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387\u201399.","journal-title":"Br J Dermatol"},{"key":"781_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18047","author":"E Sbidian","year":"2019","unstructured":"Sbidian E, Billionnet C, Weill A, et al. Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14 147 apremilast- and methotrexate-naive patients in the French National Health Insurance database. Br J Dermatol. 2019. https:\/\/doi.org\/10.1111\/bjd.18047(Epub ahead of print).","journal-title":"Br J Dermatol."},{"key":"781_CR16","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1111\/1346-8138.14617","volume":"45","author":"M Kishimoto","year":"2018","unstructured":"Kishimoto M, Komine M, Hioki T, et al. Real-world use of apremilast for patients with psoriasis in Japan. J Dermatol. 2018;45:1345\u20138.","journal-title":"J Dermatol"},{"key":"781_CR17","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/jdv.14832","volume":"32","author":"E Papadavid","year":"2018","unstructured":"Papadavid E, Rompoti N, Theodoropoulos K, et al. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018;32:1173\u20139.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"2","key":"781_CR18","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/1203475419897578","volume":"24","author":"VK Sandhu","year":"2020","unstructured":"Sandhu VK, Ighani A, Fleming P, Lynde CW. Biologic treatment in elderly patients with psoriasis: a systematic review. J Cutan Med Surg. 2020;24(2):174\u201386. https:\/\/doi.org\/10.1177\/1203475419897578.","journal-title":"J Cutan Med Surg."},{"key":"781_CR19","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1080\/14656566.2017.1409205","volume":"18","author":"A Cline","year":"2017","unstructured":"Cline A, Cardwell LA, Feldman SR. Advances in treating psoriasis in the elderly with small molecule inhibitors. Expert Opin Pharmacother. 2017;18:1965\u201373.","journal-title":"Expert Opin Pharmacother"},{"key":"781_CR20","unstructured":"European Medicines Agency. Otezla summary of product characteristics. Available from URL: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/otezla-epar-product-information_en.pdf. Accessed 1 July 2020."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00781-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-020-00781-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00781-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T23:39:38Z","timestamp":1626824378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-020-00781-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["781"],"URL":"https:\/\/doi.org\/10.1007\/s40266-020-00781-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"type":"print","value":"1170-229X"},{"type":"electronic","value":"1179-1969"}],"subject":[],"published":{"date-parts":[[2020,7,21]]},"assertion":[{"value":"21 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Other authors declare no conflicts of interest concerning this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"N. Beneton has paid activities as a consultant, advisor, or speaker for Abbvie, Celgene, Leo Pharma, Lilly, Janssen Cilag, Novartis, Pfizer, and UCB; J. Delaunay for Abbvie, Leo Pharma, Novartis, and Janssen Cilag; Z. Reguiai for Celgene, Janssen Cilag, Pfizer, Abbvie, Leo Pharma, Lilly, UCB, Medac, MSD, and Novartis; C. Boulard for Novartis, Abbvie, and Celgene; A.-C. Fougerousse for Novartis, Abbvie, Pfizer, Lilly, Celgene, and Janssen Cilag; L. M\u00e9ry-Brossard for Abbvie, Leo Pharma, Novartis, Celgene, and Janssen Cilag; D. Thomas-Beaulieu for Novartis, Abbvie, Janssen Cilag, Lilly, Leo Pharma and Celgene; J. Parier for Janssen Cilag, Novartis, Celgene, and Leo Pharma; E. Mah\u00e9 for Abbvie, Amgen, Janssen Cilag, Celgene, Leo Pharma, Lilly, Novartis, and Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}